JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
Research shows that both peptides, TB-500 and BPC-157, aid in wound healing and speed up recovery from injury, and may show synergistic effects when combined. BPC-157 (Body protection compound 157) is a synthetic derivative of a protein naturally found in human gastric juice. TB-500 is a synthetic derivative of thymosin beta 4, an endogenous peptide present in the thymus gland. On our website, TB-500 and BPC-157 blend for sale is exclusively available for research and educational purchases.
BPC-157 has been shown to promote wound healing in skin, muscle, tendon and ligaments. Recovery from tissue injury or wound healing depends on the migration and proliferation of fibroblasts. Migration of fibroblasts is an important step for the re-establishment of cellular and extracellular matrix. It secretes collagen, which helps in wound closure at the site of injury. The movement of fibroblasts is heavily dependent on protein actin. BPC-157 increases the proliferation of fibroblast, plus it upregulates the gene expression responsible for the production of actin [1]. TB-500 has been shown to promote wound healing by sequestering actin molecules at the site suitable for building filaments that facilitate cell movement [2].
Both TB-500 and BPC-157 promote angiogenesis (formation of new blood vessels) by upregulating the expression of vascular endothelial growth factor (VEGF) [3,4]. Vascular proliferation plays an important role in improving circulation, reducing cardiovascular risk and supporting recovery from injury. Together, these peptides have the potential to exhibit synergistic effects in accelerating recovery from injury. At Element Sarms, the option to buy BPC-157 and TB-500 blend is restricted to research purposes. Only purchase BPC-157 and TB-500 blend if you are a qualified researcher.
The BPC-157 + TB-500 Research Blend co-delivers 2mg of BPC-157 (CAS 137525-51-0) and 2mg of TB-500 (CAS 77591-33-4) in a single co-lyophilised vial. Each component is independently synthesised to 99%+ purity and precision-combined prior to lyophilisation, ensuring a consistent compound ratio across experimental replicates.
Researchers studying overlapping intracellular signalling pathways — including FAK pathway activation, actin polymerisation dynamics, extracellular matrix protein expression, and cell migration behaviour — frequently use both peptides within combined experimental protocols. The single-vial blend format enables concurrent investigation of both compounds within one reconstitution, reducing inter-assay variability.
Components independently verified by HPLC and Mass Spectrometry prior to blending. USA-manufactured by Element SARMs Reconstitute with bacteriostatic water. Store at -20C; stable 24 months.
WARNING: For research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
